Request Legal Help Now - Free
Advertisement
 
Home Page >> Saxagliptin marketed as Onglyza and Kombiglyze XR >> Articles

Onglyza and Kombiglyze XR Articles

More Type 2 Diabetics add Complaints to Ongoing Onglyza Litigation

More Type 2 Diabetics add Complaints to Ongoing Onglyza Litigation April 4, 2018. By Jane Mundy.
Atlanta, GA: In the past month, two more Onglyza and Kombiglyze lawsuits were filed on behalf of diabetes patients who claim the manufacturer concealed information linking the diabetes drug to an increased risk of heart failure and failed to warn about its alleged potential to cause serious heart problems.
Read [ More Type 2 Diabetics add Complaints to Ongoing Onglyza Litigation ]

Deadly Onglyza Side Effects Set in Fast and Lawsuits Lumber On

Deadly Onglyza Side Effects Set in Fast and Lawsuits Lumber On February 25, 2018. By Anne Wallace.
Pittsburgh, PA: Viola Chapman began taking Onglyza and Kombiglyze XR (Saxagliptin) to treat her type 2 diabetes in February 2015. By December, as her Onglyza lawsuit claims, those drugs had caused heart failure, congestive heart failure and cardiovascular injury.
Read [ Deadly Onglyza Side Effects Set in Fast and Lawsuits Lumber On ]

Onglyza Litigation Ramps Up

Onglyza Litigation Ramps Up January 27, 2018. By Jane Mundy.
Miami, FL: Yesterday, The U.S. Judicial Panel on Multidistrict Litigation (JPML) heard from Onglyza and Kombiglyze patients regarding whether to consolidate all federally-filed cases before one court for pre-trial proceedings.
Read [ Onglyza Litigation Ramps Up ]

‘Failure to Warn’ at Heart of Onglyza Lawsuits

‘Failure to Warn’ at Heart of Onglyza Lawsuits December 31, 2017. By Anne Wallace.
San Francisco, CA: Once the procedural wrangling is over, the argument that patients were hurt because drug manufacturers, AstraZeneca and Bristol-Meyers Squibb, failed to warn them of the dangers of Onglyza side effects will be at the heart of the Onglyza lawsuits.
Read [ ‘Failure to Warn’ at Heart of Onglyza Lawsuits ]

Onglyza Lawsuits Seek MDL Status in California

Onglyza Lawsuits Seek MDL Status in California November 4, 2017. By Anne Wallace.
San Francisco, CA: On October 11, 2017, a group of Onglyza plaintiffs filed a Motion to Transfer with the U.S. Judicial Panel on Multidistrict Litigation (JPML). The motion seeks to consolidate the Onglyza lawsuits filed throughout the federal court system in the U.S. District Court for the Northern District of California. At the time of filing, there were 44 lawsuits pending in 24 federal jurisdictions, all of which put forth virtually identical legal and factual theories. Plaintiffs foresee the possibility that hundreds of Onglyza and Kombiglyze (collectively referred to as “Onglyza” in the motion) lawsuits will be filed in the future.
Read [ Onglyza Lawsuits Seek MDL Status in California ]

Add Pancreatic Cancer to Your List of Saxagliptin Worries

Add Pancreatic Cancer to Your List of Saxagliptin Worries October 9, 2017. By Anne Wallace.
Washington, DC: While patient lawsuits have focused on the danger of heart failure as a Saxagliptin side effect, the risk of pancreatic cancer may be flying under the radar. It can be just as deadly, and research suggests a link between Saxagliptin and the disease.
Read [ Add Pancreatic Cancer to Your List of Saxagliptin Worries ]

Despite Concerns over Onglyza, FDA Keeps Going Back to the Trough

Despite Concerns over Onglyza, FDA Keeps Going Back to the Trough September 6, 2017. By Gordon Gibb.
Washington, DC: In the accepted parlance of the pharmaceutical and medical industries, a drug is considered not unsafe for the intended patient if the benefits of the drug outweigh the risk. One can therefore assume that the US Food and Drug Administration (FDA) took this mantra to heart in 2009 when the federal regulator approved Onglyza (saxagliptin) in spite of reservations over potential saxagliptin side effects and the results of clinical trials associated with Onglyza conducted before the drug was approved.
Read [ Despite Concerns over Onglyza, FDA Keeps Going Back to the Trough ]

California Saxagliptin Lawsuit Plaintiffs Score Big Procedural Win

California Saxagliptin Lawsuit Plaintiffs Score Big Procedural Win August 11, 2017. By Anne Wallace.
Washington, DC:Saxagliptin lawsuit plaintiffs just got a big victory. The fact that they can sue in California courts under California law will affect whether and how much they can recover for the injuries they have suffered.
Read [ California Saxagliptin Lawsuit Plaintiffs Score Big Procedural Win ]

Onglyza, Kombiglyze Maintain Risks in Spite of Dismissed Lawsuits

Onglyza, Kombiglyze Maintain Risks in Spite of Dismissed Lawsuits July 22, 2017. By Gordon Gibb.
Trenton, NJ: Plaintiffs bringing either a saxagliptin lawsuit, or an Onglyza lawsuit (Onglyza is the trade name for saxagliptin) appear to have had a checkered track record in terms of success with their cases in spite of various side effects associated with the Type 2 diabetes drug.
Read [ Onglyza, Kombiglyze Maintain Risks in Spite of Dismissed Lawsuits ]

New Jersey Man Claims Diabetes Medicine Caused His Heart Disease

New Jersey Man Claims Diabetes Medicine Caused His Heart Disease June 27, 2017. By Deb Hipp.
Trenton, NJ: A New Jersey man has filed a federal lawsuit against drug manufacturers Bristol-Myers Squibb and Astrazeneca Pharmaceuticals, claiming he suffered injuries after taking the diabetes drug Saxagliptin, sold under the brand names Onglyza and Kombiglyze XR.
Read [ New Jersey Man Claims Diabetes Medicine Caused His Heart Disease ]

Request Legal Help Now! - Free